GlassScriptPhysician profile
Suzanne B Grimm
NPI 1245345230
$3,260.46
in general payments reported to CMS, 2019-2025
22 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $157 · 2021: $71.98 · 2022: $32.86 · 2023: $273 · 2024: $646 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.16 |
| Education | $187.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $472.48 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $411.72 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $398.94 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $394.84 | 2019-2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $235.62 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $209.71 | 2019-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.56 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $116.84 | 2019 | |
| Axsome Therapeutics, INC. | $116.62 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $113.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $100.61 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $94.51 | 2019 | |
| Allergan, INC. | $74.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $72.31 | 2019-2025 | |
| Vertical Pharmaceuticals, LLC | $54.19 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $52.61 | 2021-2022 | |
| Neos Therapeutics, LP | $51.97 | 2019 | |
| Indivior INC. | $50.08 | 2023-2024 | Perseris |
| Jazz Pharmaceuticals INC. | $37.72 | 2019 | |
| Bausch Health US, LLC | $34.28 | 2019 | |
| Adlon Therapeutics L.P. | $27.34 | 2019 | |
| Acadia Pharmaceuticals INC | $17.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.